Fortis Healthcare has reported a significant 22% year-on-year decline in its consolidated profit after tax (PAT) for the third quarter ending December 2025. The net profit fell to 197 crore, down from 254 crore in the corresponding period last year. This dip was primarily driven by an exceptional loss of 55.2 crore, largely attributed to the implementation of new labor codes. Despite the bottom-line pressure, operational revenue showed strong resilience. Top-line income grew by 17.5% to 2,265 crore, compared to 1,928 crore in the previous year. This growth was fueled by robust performance in specialized clinical areas, specifically renal sciences and orthopedics, which saw growth of 27% and 20% respectively. Market performance for Fortis stock remains a focal point for investors. As of February 13, 2026, the share price closed at 918.80 on the NSE, reflecting a 1.05% intraday decline following the earnings announcement. The company currently maintains a market capitalization of approximately 69,180 crore, with shares trading between a 52-week high of 1,104.30 and a low of 587.10. Strategically, the group is aggressively pursuing an expansion-led growth model. A key highlight this quarter was the acquisition of the 125-bedded People Tree Hospital in Bengaluru for 430 crore. This move is part of a broader plan to scale its presence in the Bengaluru cluster from 900 beds to over 1,500 beds in the near future. The broader Indian healthcare sector is currently benefiting from a favorable policy environment following the Union Budget 2026. The budget has repositioned healthcare as a vital economic infrastructure, introducing the 10,000 crore Biopharma Shakti program and establishing five regional medical tourism hubs. These initiatives are expected to drive long-term demand for private hospital operators. Current industry trends indicate a steady rise in Average Revenue Per Occupied Bed (ARPOB), which has increased by 10% to 16% across leading networks. This shift is driven by a move toward higher-acuity procedures in oncology and neurology. Furthermore, the diagnostics segment remains a high-margin contributor, with top players reporting EBITDA margins between 25% and 35%. Looking ahead, Fortis aims to mitigate one-time costs through improved operational leverage and network optimization. With a net debt-to-EBITDA ratio sitting comfortably at 0.41x, the company is well-positioned for further inorganic growth and capacity additions across its mature hospital assets.